Best Options Strategy for IMVT
Looking for the best options strategy for Immunovant, Inc. (IMVT)? There is no single answer — the right play depends on your outlook, your risk tolerance and current implied volatility. Below, our free engine shows the highest-scoring defined-risk strategy on the live IMVT option chain right now, and a simple map from your view on IMVT to the strategy that fits it. Model any of them in the calculator before you trade.
About IMVT
Immunovant, Inc. (IMVT) is a major company in Biotechnology. Options traders on IMVT tend to watch , since these can drive large moves in the share price.
About Immunovant, Inc.
Immunovant is a clinical-stage biotech company focused on developing treatments for autoimmune diseases. Its primary candidate is IMVT-1402, a monoclonal antibody designed to block a specific immune pathway involved in several conditions. The company is investigating this single therapeutic approach across multiple autoimmune indications, including Graves' disease, rheumatoid arthritis, Sjögren's disease, cutaneous lupus erythematosus, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. Founded in 2018 and headquartered in Durham, North Carolina, Immunovant operates as a subsidiary within the Roivant Sciences portfolio.
Currently, Immunovant generates no revenue from product sales, as IMVT-1402 remains in clinical development and has not yet received regulatory approval. The company's finances depend on funding from its parent company, Roivant Sciences, which itself operates as a specialty biotech holding company. Immunovant's path to profitability is contingent on successfully advancing IMVT-1402 through late-stage clinical trials, obtaining FDA approval for one or more of its targeted indications, and eventually commercializing the therapy in markets where…
Today's top-scoring strategy for IMVT
Our engine ranks defined-risk strategies on the live IMVT chain by probability of profit and risk/reward, then surfaces the best-scoring one. It is an educational illustration, not advice.
| Action | Qty | Type | Strike | Premium |
|---|---|---|---|---|
| Sell | 1× | CALL | $40 | $0.28 |
| Buy | 1× | CALL | $42 | $0.05 |
Simulation
Forward simulation of 6,000 lognormal price paths to expiration — not a historical backtest.
Illustrative example at IMVT's latest available price, computed with the same engine as the tool. Live option fills and the real IV skew refresh during US market hours.
Implied volatility
IMVT is currently trading with moderate implied volatility, broadly in line with other large-cap stocks. On the options we scanned that was around 32% implied volatility, and higher implied volatility means richer premiums and wider expected moves.
Options on IMVT currently price in about 32% implied volatility, versus roughly 97% the stock has actually realised over the past month. That makes options relatively cheap — an edge for strategies that buy premium, such as long calls, long puts and debit spreads.
Off that volatility, the options market is pricing a move of about ±$2.4 (±6%) in IMVT by 2026-07-17 — a range of roughly $35.58 to $40.38. Strikes inside that band hold most of the premium and see most of the action.
Across strikes, downside puts on IMVT trade at a higher implied volatility than upside calls — the market is paying up for crash protection. That skew favours selling put spreads or buying calls over symmetric trades.
Earnings & IV crush
IMVT's next earnings report is due around August 10, 2026. Options that expire after it price in a binary move, so their implied volatility is elevated and usually collapses right after the announcement — an "IV crush". If your expiration falls before this date, the trade sidesteps the event.
Key figures
- Market cap
- $8.0B
- Beta (vs market)
- 0.79
- 52-week range
- $14.32–$39.28 (95% up the range)
- Short interest
- 21.3% of float · 7.7 days to cover
With 21.3% of IMVT's float sold short, squeeze and gap risk are elevated — one reason its options can stay expensive.
How to choose an options strategy for IMVT
Start with your outlook on IMVT, then match it to a defined-risk structure. Here are the most common choices and when each makes sense:
Bullish
Buy a call for leverage with capped risk, or a bull call spread to lower the cost and breakeven when you have a target price.
Long Call → Bull Call Spread →Bearish
Buy a put to profit from a decline with defined risk, or a bear put spread to cheapen the trade when you expect a measured move down.
Long Put → Bear Put Spread →Neutral
Sell an iron condor to collect premium while IMVT stays between two strikes, or write a covered call against shares you already own.
Iron Condor → Covered Call →How we pick the best strategy
For each ticker we pull the live option chain, build every supported strategy around the at-the-money strikes, and score them on probability of profit, risk/reward and capital efficiency — favouring defined-risk structures where the maximum loss is known up front. Methodology →
Open IMVT in the free calculator →
Frequently asked questions
What is the best options strategy for IMVT?
It depends on your outlook. Bullish traders often use a long call or bull call spread on IMVT; bearish traders a long put or bear put spread; neutral traders an iron condor or covered call. Our live scan above shows the current highest-scoring defined-risk play.
Are IMVT options liquid enough to trade?
Immunovant, Inc. (IMVT) is among the most actively-traded US options, which usually means tight bid/ask spreads and plenty of strikes and expirations — though you should always check the open interest and spread on the exact contract.
How much money do I need to trade IMVT options?
Buying a single IMVT call or put can cost as little as the premium (often one to a few hundred dollars), while income strategies like a cash-secured put need enough capital to buy 100 shares if assigned.
Is this financial advice?
No. Everything here is educational and uses delayed, third-party data. It is not a recommendation to trade IMVT or any security. Do your own research.
What does Immunovant, Inc. do?
Immunovant, Inc. (IMVT) operates in the Biotechnology industry. The "About Immunovant, Inc." section above gives a fuller picture of what the company does and how it earns money.
Does Immunovant, Inc. pay a dividend?
Immunovant, Inc. does not currently pay a dividend, so there is no ex-dividend assignment risk to plan around for options strategies.
When does Immunovant, Inc. next report earnings?
Immunovant, Inc.'s next earnings are expected around August 10, 2026. Implied volatility usually climbs into the report and drops sharply afterwards (IV crush) — important for any options position held over the date.
Tickers related to IMVT
Comparing IMVT with similar names can help you choose the best options strategy:
Company information
- Headquarters
- 1000 Park Forty Plaza, Suite 210, Durham, NC, 27713, United States
- Industry
- Biotechnology
- Employees
- 315
- CEO
- Dr. Eric Venker M.D., Pharm.D.
- Phone
- 917 410 3120
- Website
- immunovant.com
Best Options Strategy by Ticker →
Educational use only. Quotes are delayed ~15 minutes and nothing here is financial advice. Options trading involves substantial risk of loss. Privacy · Terms.